Showing 1131-1140 of 1572 results for "".
- Long-term Disease Control in NSCLC: Outcomes Post-Immunotherapy Discontinuationhttps://reachmd.com/news/long-term-disease-control-in-nsclc-outcomes-post-immunotherapy-discontinuation/2474201/Retrospective studies have highlighted that a segment of non-small cell lung cancer (NSCLC) patients who cease immunotherapy due to immune-related adverse events (irAEs) continue to sustain disease control. This exploration delves into clinical observations and potential im
- Advanced Imaging in NSCLC: A New Frontier for Lymph Node Metastasis Detectionhttps://reachmd.com/news/advanced-imaging-techniques-in-non-small-cell-lung-cancer-evaluating-lymph-node-metastases/2474148/In the evolving landscape of thoracic oncology, the quest for precision in staging non-small cell lung cancer (NSCLC) has ushered in a new generation of imaging tools. Among the most promising is multiparametric 18F-FDG PET/MRI—a hybrid modality that fuses metaboli
- Protein Involvement in Parkinson's Disease and Its Implications for Melanomahttps://reachmd.com/news/protein-involvement-in-parkinsons-disease-and-its-implications-for-melanoma/2474086/Recent investigations have expanded our understanding of alpha-synuclein, a protein recognized for its role in Parkinson's disease. This protein has now been found to enhance DNA repair in melanoma cells, thereby promoting tumor progression. Studies from
- Navigating Resistance: Mutation Profiles and Treatment Challenges in EGFR-Mutated NSCLChttps://reachmd.com/news/navigating-resistance-mutation-profiles-and-treatment-challenges-in-egfr-mutated-nsclc/2471835/Recent reviews underline distinct resistance mutation profiles in EGFR-mutated non-small-cell lung cancer, underscoring mechanisms like T790M loss and newly emerging C797X mutations that affect both first- and second-line osimertinib treatments.
- riSCC App Launched for Risk Stratification of cSCChttps://reachmd.com/news/riSCC-App-Launched-Risk-Stratification-cSCC/2471817/The not-for-profit organization Skin Cancer Consortium Outcomes (SCOUT) announced it has launched riSCC, a data-driven clinician mobile app designed for risk stratification of cutaneous squamous cell carcinoma (cSCC) in clinical settings. SCOUT, founded in 2018, is committed to transformi
- Decoding the Genetic Evolution of Prostate Cancer: Inherited Variants and Tumor Progressionhttps://reachmd.com/news/decoding-the-genetic-evolution-of-prostate-cancer-inherited-variants-and-tumor-progression/2471530/Uncovering the Dual Genetic Drivers of Prostate Tumor Progression Recent studies have revealed that inherited genetic variants not only predispose prostate cells to acquire specific somatic mutations but also set a common evolutionary pathway that determines tumor
- Exploring the Emerging Threat of Bat-Derived Viruses: Insights from HKU5-CoV-2https://reachmd.com/news/exploring-the-emerging-threat-of-bat-derived-viruses-insights-from-hku5-cov-2/2471412/Deciphering the Cross-Species Transmission of a Novel Bat-Derived Virus Recent investigations have spotlighted HKU5-CoV-2, a bat-derived virus capable of infecting human cells via the ACE2 receptor. This article examines its infection dynamics in human organoid mod
- Surgical Excision Outperforms Curettage Plus Imiquimod for nBCChttps://reachmd.com/news/surgical-excision-outperforms-curettage-plus-imiquimod-for-nbcc/2471123/Surgical excision (SE) is significantly more effective than superficial curettage (SC) followed by imiquimod cream, 5%, in maintaining tumor-free survival for nodular basal cell carcinoma (nBCC) after five years, according to a new analysis in JAMA Dermatology.
- Unveiling the Role of Granzyme K in Chronic Inflammatory Diseaseshttps://reachmd.com/news/unveiling-the-role-of-granzyme-k-in-chronic-inflammatory-diseases/2471106/Quick Summary Granzyme K, a protein largely expressed by CD8+ T cells, has been identified as a key driver in activating the complement system, leading to inflammation and tissue damage in autoimmune diseases. This discovery offers new therapeutic possibilities for
- Heart Transplant Patients Show Increased Skin Cancer Incidence: Meta-Analysishttps://reachmd.com/news/heart-transplant-patients-show-increased-skin-cancer-incidence-meta-analysis/2470902/Heart transplant (HTx) recipients face a 16% overall risk of developing skin cancer, with squamous and basal cell carcinomas being the most common forms, a new meta-analysis indicated. "Studies have shown that patients who undergo HTx are at an increased risk for developing skin cancer," t